Day 1 – Tuesday 8th October - CET (Central European Time, GMT+01:00)
Day 1 – Tuesday 8th October - CET (Central European Time, GMT+01:00)
- Josh Dance - Managing Director, LSX
- Adam Kostyál - President, Nasdaq
- Carsten Borring - Head of Listings & Capital Markets, NASDAQ
- Adam Kostyál - President, Nasdaq
- Christof Bischoff - Country Director, Denmark, AstraZeneca
- Stephan Christgau - Founding Partner, Eir Ventures
- Henrijette Richter - Partner , Sofinnova Partners
- Bogi Eliasen - Director of Health, Copenhagen Institute for Future Studies
- Troels Bierman Mortensen - CEO, DataFair
- Frederik Knud Nielsen - Healthcare Partnerships Director, Novartis Denmark
- Kenneth Forsstrøm Jensen - Health Data Lead, Roche
- Renee Aguiar-Lucander - CEO, Calliditas Therapeutics
- Jens Lindberg - CEO, Medivir
- Per Andersson - CEO, Xspray pharma
- Søren Bregenholt - CEO, Alligator Biosciences
- Giovanni Rizzo - Partner Biotech Fund, Indaco Venture Partners
- Jeroen Bakker - Partner, Novo Holdings
- Ingrid Teigland Akay - Managing Partner, Hadean Ventures
- Ward Capoen - Partner, V-Bio Ventures
The anticipation and excitement around AI is huge, how are these novel technologies shaping the industry? How can we apply these new technologies into healthcare, and overcome social, ethics & regulatory barriers to implementation?
- Leveraging generative AI tools & large language models to solve unmet medical needs and optimise care delivery
- EU AI Act – How will this legislation affect digital health and medtech companies? • AI use to improve the patient and consumer experience – what about less obvious use cases for AI?
- Managing consumer and patient expectations in the age of AI
- Effective safeguards for responsible AI use (ethical frameworks, diversity & inclusion in AI development etc.)
- Farzaneh Etminani - AI Strategist, Region Halland
- Lauri Sippola - Co-founder & CEO, Gosta Labs
- Jussi Leinonen - Strategic Project Lead, Bayer
- Henriikka Halinen - Business Leader, Emergency Care, Western Europe, Philips
- Evaluating the reimbursement pathways and frameworks across Europe
- Where are we at? Which countries pathways/ frameworks are working best
- Overcoming barriers of adoption
- Strategies for thriving in Europe's fragmented digital health markets
- Expanding and scaling into a new market – success stories
- Magnus Nyden - Head of Innovation, AstraZeneca
- Beth Wolff - Director Digital Health Solutions, Global Corporate Strategy & BD, Lundbeck
- Hisham Hamadeh - SVP, Global Head of Data Science & AI, Genmab
- Kaari Kink - Investment Manager, Superangel
- Linda Võeras - Early Stage Investor, Karma Ventures
- Tim Vaino - Investment Manager, Change Ventures
With the appetite for in-house R&D increasingly reducing for big Medtech and Pharma, the opportunity is ripe for medtech and healthtech companies to position themselves as the next ‘must-have’ partner. This panel takes a look at the current deal-making market, and how big strategics are playing their cards.
- How has the sector recovered and processed the deal overhang in 2024?
- Making your company ‘acquisition & partnership’ ready
- What happens ‘behind the scenes’ as a deal is negotiated?
- Large medtech and pharma and private equity deal appetite for 2025
- VC funding model – how well is this working in reality?
- Surviving the drought - creative financing measures in a capitalconstrained environment
- Has 2024 been the year of consolidation? Who are the winners? Big pharma, big medtech or large healthtech companies?
- Evaluating recent investor decisions - Why did you choose to invest? Do investors feel the valuations have been the right size?
- Bobby Soni - CBO, BII
- João Ribas - Principal, Novo Holdings
- Kristian Tryggvason - Co-founder, CEO, Alder Therapeutics
- Stephanie Munk - Senior Associate, Sunstone Life Science Ventures
- Keld Flintholm Jørgensen - SVP & CBO, Lundbeck
- Jane Buus Laursen - CVP, Corporate Development, Novo Nordisk
- Bradley Hardiman - Senior Director, Ventures, Business development, Astellas Pharma
The biggest market with the clearest opportunity for scale, investors will shy away from medtech and healthtech companies without a clear plan of attack for the US market. This panel looks at what it takes to scale across the pond, and the tips and tricks needed in your back-pocket for success.
- Building your base in the U.S
- Access and regulatory cheatsheet
- Commercialising from a home to international market – mishaps and missteps
- Building effective relationships with public healthcare providers
- How can companies improve adoption and implementation?
- What truly augments practitioner and patient experience?
- Has AI adoption brought enough value to healthcare?
- The increasing importance of sustainability for hospitals